MADRIGAL PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $7.93 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-31.
Discontinued › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2017-03-31
- MADRIGAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2016 was $7.93M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|
| 2016-12-31 | $7.93M 10-K · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |